Fed Unveils Stablecoin Rules Under GENIUS Act 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
Dubai’s connectivity remains strong in an uncertain world 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
OpenAI Agent Breaches Australia Medicare Data Portal 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
Add as a preferred source on Google
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
